We are live on ! Find out more

125 hedge funds and large institutions have $480M invested in Erasca in 2024 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

221% more capital invested

Capital invested by funds: $150M → $480M (+$331M)

122% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 23

86% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 21

50% more funds holding in top 10

Funds holding in top 10: 46 (+2)

30.24% more ownership

Funds ownership: 48.1%78.34% (+30%)

16% more funds holding

Funds holding: 108125 (+17)

84% less call options, than puts

Call options by funds: $79K | Put options by funds: $487K

Holders
125
Holders Change
+17
Holders Change %
+15.74%
% of All Funds
1.81%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
39
Increased
51
Reduced
23
Closed
21
Calls
$79K
Puts
$487K
Net Calls
-$408K
Net Calls Change
-$316K
Name Holding Trade Value Shares
Change
Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$38.3M +$35M +16,216,216 New
VA
2
VR Adviser
New York
$38.3M +$35M +16,216,216 New
SCM
3
Suvretta Capital Management
New York
$32.5M +$29.7M +13,768,039 New
AVM
4
Arch Venture Management
Illinois
$26.1M
BlackRock
5
BlackRock
New York
$25M +$7.83M +3,630,176 +52%
Vanguard Group
6
Vanguard Group
Pennsylvania
$24.4M +$13M +6,013,638 +139%
AG
7
Artal Group
Luxembourg
$22.7M +$10.6M +4,909,616 +104%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$19.3M +$17.6M +8,178,092 New
SCM
9
Silverarc Capital Management
Massachusetts
$18.4M +$16.4M +7,593,081 +3,392%
T. Rowe Price Investment Management
10
T. Rowe Price Investment Management
Maryland
$17.4M +$15.9M +7,374,359 New
PBA
11
Paradigm Biocapital Advisors
New York
$17.1M +$15.6M +7,250,000 New
VC
12
Vivo Capital
California
$15.9M +$14.6M +6,756,756 New
LGM
13
Logos Global Management
California
$13.9M +$12.7M +5,900,000 New
5VM
14
5AM Venture Management
California
$12.8M +$11.7M +5,405,404 New
PHS
15
PFM Health Sciences
California
$11M +$4.61M +2,136,672 +84%
Balyasny Asset Management
16
Balyasny Asset Management
Illinois
$10.2M +$9.32M +4,319,484 New
WP
17
Woodline Partners
California
$9.76M +$7M +3,243,243 +364%
Marshall Wace
18
Marshall Wace
United Kingdom
$8.67M +$7.92M +3,672,375 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$7.82M +$3.06M +1,420,348 +75%
Citadel Advisors
20
Citadel Advisors
Florida
$7.77M +$5.3M +2,456,057 +293%
SCM
21
Sio Capital Management
New York
$6.78M +$965K +447,352 +18%
ACM
22
AH Capital Management
California
$6.76M
PM
23
Prosight Management
Texas
$6.49M -$1.96M -909,755 -25%
AAA
24
Affinity Asset Advisors
New York
$5.9M +$5.39M +2,499,431 New
State Street
25
State Street
Massachusetts
$5.8M +$1.7M +787,495 +47%

ERAS Hedge Fund Activity: Q2 2024 in Review

125 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Erasca (ERAS) for Q2 2024, worth a combined $480M — up 221% from $150M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ERAS positions and 21 closed out — a net gain of 18 holders — while 51 added to existing stakes and 23 trimmed.

The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $35M. The largest seller was Armistice Capital, exiting entirely with an estimated $12.7M sold.

  • 125 institutional investors held Erasca (ERAS) as of Q2 2024, up from 108 in Q1 2024.
  • Funds reported $480M of Erasca stock for Q2 2024, up 221% quarter-over-quarter.
  • 39 funds opened new Erasca positions in Q2 2024 and 21 closed out, a net change of +18 holders.
  • The largest Erasca buyer in Q2 2024 was Frazier Life Sciences Management, an estimated $35M added.
  • The largest Erasca seller in Q2 2024 was Armistice Capital, an estimated $12.7M sold.

Based on aggregated 13F filings for Q2 2024.